在患有抗卵巢癌的患者中,重新挑战基于的化疗:一项队列研究
Carmine Valenza1, Marta Mongillo2, Maria Vittoria Visconti3
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Harvard Chan School of Public Health, Harvard University, Boston, MA, USA.
Gynecologic oncology
|February 9, 2025
概括
重新挑战对以前接受非方案的抗性卵巢癌患者来说是有前途的. 这种策略提供了一个可行的选择,建议在治疗期间动态重新评估基疗法.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 临床癌症研究 临床癌症研究
背景情况:
- 基于的化疗是卵巢癌治疗的基石.
- 抗性需要使用替代治疗策略.
- 在卵巢癌中使用非白金疗法后,对白金再试剂的数据有限.
研究的目的:
- 为了评估白金再挑战在患有白金耐药卵巢癌的患者的疗效.
- 在这个患者群体中评估无进展生存率 (PFS) 和反应率.
- 为卵巢癌患者在非白金疗法后进展的治疗决策提供信息.
主要方法:
- 对30名高度卵巢癌患者进行了回顾性队列研究.
- 纳入标准:至少经过一次非治疗后,获得了抗性疾病.
- 收集的数据:白金再挑战剂 (碳白金/白金),先前的治疗线,PFS和反应率.
主要成果:
- 目标应答率 (ORR) 为27% (95% CI: 12-46%),疾病控制率 (DCR) 为80% (95% CI: 61-92%).
- 中位数的PFS为5.4个月 (95% CI:2.5-8.2).
- 六个月的PFS率为47% (95% CI:28-63%).
结论:
- 再挑战是一种可行的治疗选择,可用于选择的抗性卵巢癌患者.
- 这种方法可能对以前接受过非化疗的患者有益.
- 建议对在治疗顺序中的作用进行动态重新评估.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...